Memento Medicines Raises $93 Million Series A For Retinal Disease Therapy
By Amit Chowdhry ● Jun 20, 2026
Memento Medicines announced the completion of a $93 million Series A financing round to advance MMT-205, its lead biologic therapy for retinal diseases. The round was co-led by Forbion, RA Capital Management, and Avego BioScience Capital, with participation from Sanofi Ventures and Samsara BioCapital.